119 related articles for article (PubMed ID: 9695574)
21. Monoclonal antibodies reactive with different sites of N and H antigenic particles of poliovirus.
Taniguchi K; Urasawa S; Urasawa T
J Gen Virol; 1983 Dec; 64 ( Pt 12)():2803-8. PubMed ID: 6198442
[TBL] [Abstract][Full Text] [Related]
22. Comparison between indirect immunofluorescence and microneutralization for detection of antibodies to polioviruses.
Pettit C; Minnich LL; Shehab ZM; Ray CG
J Clin Microbiol; 1987 Jul; 25(7):1325-6. PubMed ID: 3038952
[TBL] [Abstract][Full Text] [Related]
23. A human-human hybridoma which produces antibodies to polioviruses.
Chu CT; Yang SY; Yang CS
Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):284-8. PubMed ID: 2561573
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies reveal in blocking reactions the antigenicity and antibody response of poliovirus.
Uhlig H; Rutter G; Dernick R
Dev Biol Stand; 1984; 57():187-91. PubMed ID: 6084610
[TBL] [Abstract][Full Text] [Related]
25. [Use of monoclonal antibodies for the intratypic differentiation of strains of poliomyelitis type I virus].
Lashkevich VA; Mustafina AN; Koroleva GA; Gracheva LA; Grishina KG
Vopr Virusol; 1987; 32(2):183-8. PubMed ID: 2440185
[TBL] [Abstract][Full Text] [Related]
26. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
[TBL] [Abstract][Full Text] [Related]
27. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
Ferguson M; Minor PD; Magrath DI; Schild GC
Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
[TBL] [Abstract][Full Text] [Related]
28. [Use of a microtechnic for the serological intratype identification of poliovirus strains 1 and 3].
Stewien KE; Lacerda JP
Rev Saude Publica; 1977 Mar; 11(1):135-42. PubMed ID: 193175
[No Abstract] [Full Text] [Related]
29. Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies.
Emini EA; Jameson BA; Lewis AJ; Larsen GR; Wimmer E
J Virol; 1982 Sep; 43(3):997-1005. PubMed ID: 6183443
[TBL] [Abstract][Full Text] [Related]
30. Analysis of neutralization-escape mutants selected from a mouse virulent type 1/type 2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted.
Couderc T; Martin A; Wychowski C; Girard M; Horaud F; Crainic R
J Gen Virol; 1991 Apr; 72 ( Pt 4)():973-7. PubMed ID: 1707949
[TBL] [Abstract][Full Text] [Related]
31. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
[TBL] [Abstract][Full Text] [Related]
32. Determination of type 1 poliovirus subtype classes with neutralizing monoclonal antibodies.
Crainic R; Couillin P; Cabau N; Boue A; Horodniceanu F
Dev Biol Stand; 1981; 50():229-34. PubMed ID: 6176486
[TBL] [Abstract][Full Text] [Related]
33. WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains.
Ferguson M; Magrath DI; Minor PD; Schild GC
Bull World Health Organ; 1986; 64(2):239-46. PubMed ID: 3017595
[TBL] [Abstract][Full Text] [Related]
34. Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.
Ferguson M; Reed SE; Minor PD
J Gen Virol; 1986 Nov; 67 ( Pt 11)():2527-31. PubMed ID: 2431104
[TBL] [Abstract][Full Text] [Related]
35. [Antigen differences of genetic variants Abent+ and Abent- poliovirus vaccine strain of III type].
Shyrobokov VP; Kostenko IH; Nikolaienko IV
Mikrobiol Z; 2003; 65(4):29-36. PubMed ID: 14618784
[TBL] [Abstract][Full Text] [Related]
36. [Antigenicity determination of inactivated poliovirus--the micro-neutralization inhibition test].
Jiang SD; Pye D
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Aug; 7(4):309-12. PubMed ID: 3011295
[No Abstract] [Full Text] [Related]
37. Neutralization epitope patterns of poliovirus strains isolated from cases of acute spinal paralysis and from healthy vaccinated children.
Persu A; Combiescu M; Murg B; Aubert-Combiescu A
Roum Arch Microbiol Immunol; 1995; 54(1-2):53-63. PubMed ID: 8993114
[TBL] [Abstract][Full Text] [Related]
38. Intertypic cross-neutralization of polioviruses by human monoclonal antibodies.
Uhlig H; Dernick R
Virology; 1988 Mar; 163(1):214-7. PubMed ID: 2831657
[TBL] [Abstract][Full Text] [Related]
39. Antigen chimaeras of poliovirus as potential new vaccines.
Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
[TBL] [Abstract][Full Text] [Related]
40. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies.
Singer C; Knauert F; Bushar G; Klutch M; Lundquist R; Quinnan GV
J Biol Stand; 1989 Apr; 17(2):137-50. PubMed ID: 2541133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
